X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Ecopipam Hydrochloride, a novel investigational compound that is being studied as a potential treatment for Tourette Syndrome, by blocking the action of the neurotransmitter dopamine at the D1 receptor.
Lead Product(s): Ecopipam
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2023
Details:
Ecopipam hydrochloride is a first-in-class dopamine-1 receptor antagonist which blocks the actions of the neurotransmitter dopamine at the D1 receptor. It is currently approved to treat tourette syndrome.
Lead Product(s): Ecopipam
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
Ecopipam Hydrochloride, a novel investigational compound that is being studied as a potential treatment for certain central nervous system disorders, by blocking the action of the neurotransmitter dopamine at the D1 receptor.
Lead Product(s): Ecopipam
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2023
Details:
The study is evaluating ecopipam, an investigational first-in-class drug, to determine whether it may help improve the ability to get words out without stuttering.
Lead Product(s): Ecopipam
Therapeutic Area: Neurology Product Name: EBS-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2021
Details:
First adult patient has been dosed in its Phase 2 clinical trial evaluating ecopipam, the company’s investigational medicine, for the treatment of childhood-onset fluency disorder, or “stuttering.”
Lead Product(s): Ecopipam
Therapeutic Area: Neurology Product Name: EBS-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of California
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
